Recurrent Childhood Soft Tissue Sarcoma Completed Phase 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00030667Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of ChildhoodTreatment